Environmental or nutritional estrogenic toxicants are thought to mediate developmental and carcinogenic pathologies. Estrogen receptor (ER) measurements are currently used to predict hormonal responsiveness; therefore all ER subpopulations should be considered. We have been involved in the immunoidentification and characterization of membrane steroid receptors in several systems and have recently shown that binding of estradiol (E2) to a subpopulation of ERs (mER) residing in the plasma membrane of GH3 pituitary tumor cells mediates the rapid release of prolactin (PRL). Here we review these findings and present other important characterizations of these receptors such as trypsin and serum susceptibility, movement in the membrane, confocal localization to the membrane, binding to and function of impeded ligands, and immunoseparation of cells bearing mER. We plan to use this system as a model for both the physiological and pathological nongenomic effects of estrogens and estrogenic xenobiotics. Specifically, it should be useful as an in vitro assay system for the ability of estrogenic xenobiotics to cause rapid PRL release as an example of nongenomic estrogen effects. -Environ Health Perspect 1 03(Suppl 7): 41-50 (1995) 
Introduction
There are many known instances of estrogen toxicity that affect development and function of reproductive systems in humans and animals (1, 2) . Estrogen has been shown to have a role in initiating diseases (induding cancer) in a variety of tissues (3) (4) (5) . As more sensitive assays for estrogen receptors (ERs), their mRNAs, and their functions become available (6) , more tissues will be considered for these actions by estrogens. Understanding the toxicity of estrogen and the myriad synthetic and naturally occurring estrogenic compounds (1, 2, 7) requires an understanding of whether their effects are being mediated through genomic or nongenomic mechanisms.
The genomic actions of estrogens and other steroid hormones are now relatively well understood. In this pathway, hormones, bind to a cytoplasmic/nuclear receptor, which binds to DNA and triggers RNA-dependent protein synthesis (8, 9) . However, this mechanism best explains temporally delayed effects because it requires a series of macromolecular syntheses and protein localizations to produce responses over time periods of several hours to days (10) . Steroids and their mimetics also exert a variety of short-term effects (seen in seconds to minutes) on their target organs. For example, estradiol (E2) rapidly affects monovalent and divalent cation transport, glucose uptake, and water imbibition in the rat uterus (11) . In neurons and GH3 pituitary tumor cells, estrogens can elicit changes in electrical activity within minutes (12) (13) (14) (15) (16) . A fast action of estrogen mediates calcium mobilization in granulosa cells (17) and osteoblasts (18) . Rapid electrical responses to estrogens also occur in several areas of the brain and other tissues (15, 16, (18) (19) (20) (21) (22) (23) . Many fast or otherwise mechanistically unexplained actions of other steroids have also been reported (17, (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) . Plasma membrane-resident forms of steroid receptors have been proposed to mediate such actions (36, 37) .
Although the action of a membrane-resident steroid receptor is implied in the systems described above, only some of these studies actually attempted to demonstrate the presence of such a protein in the membrane. Several groups have provided evidence for the binding of labeled steroid to a membrane-associated site (29, (36) (37) (38) (39) (40) (41) (42) . We have developed techniques that rely mainly on the immunological detection and isolation of steroid hormone receptors residing in plasma membranes (43) (44) (45) (46) (47) (48) Cells were viewed on a Zeiss fluorescence microscope using a 63X oil immersion Planapo lens and rhodamine filter, except where indicated. The amount of time for a metered exposure of a positive response was used as a standard for subsequent photographs of negative controls. Photomicrographs were taken with T-MAX 400 film (Eastman Kodak, Rochester, NY). PRL Rdease in Response to E2 and E2-BSA 170-E2 (Sigma) was diluted in ethanol to a 1 mM concentration; a further dilution was made in phenol red-free RPMI 1640 supplemented with 25 mM HEPES. The final concentration of ethanol was 0.001%. 1,3,5(10) Estratriene-3,17P diol 6-one 6-carboxymethoxime: BSA (E2-BSA) was obtained from Steraloids (Wilton, MA). The ratio of estrogen to BSA in this preparation was 15 to 20:1. The conjugate was dissolved in deionized water to a concentration of 1 mg/ml then treated with dextran/charcoal (0. 5%/5% in PBS) immediately before dilution to remove free steroid. Subsequent dilutions were made in phenol red-free RPMI 1640 supplemented with 25 mM HEPES.
For the PRL release assays depicted in Figure 1 , cells were subcultured for 2 (Figures 2,3 ). Then, steroid or vehicle treatments in rat saline (150 mM NaCl, 5.6 mM KCI, 2 mM CaCl2, 1 mM MgCI2, 10 mM HEPES, pH 7.35, and 10 mM glucose) were added to the well for the specified amount of time. There was no significant difference in the magnitude of stimulated release in these two paradigms. Because larger numbers of cells were used in these assays, the secreted PRL level was measurable without a preincubation-accumulation of higher levels of hormone.
The concentrations of PRL in the media were determined by RIA (54) Figure 4A appears on only 8 to 17% of the cells (48) .
Other membrane-resident steroid receptors have been shown to be attached to the plasma membrane in such a way that exposure of intact cells to mild trypsin treatment removed the antigen from the cell surface (43, 46) . To further examine the possibility of cell surface localization for ER, we subjected live cells to mild trypsin digestion and checked for the presence of antigen. This treatment resulted in complete elimination of surface ER immunoreactivity ( Figure 4C ) and shows that the ER membrane labeling depends on the integrity of membrane proteins. Because trypsin has no access to the intracellular receptors, this action supports an outer-face plasma membrane localization. This also confirms the utility of Ab-based identification techniques for this class of steroid receptors, as we have shown previously for mGR (43) (44) (45) (46) (57, 58) . Confocal laser microscopy is an alternative technique for establishing cellular localization of a protein by optical sectioning through a fluorescently labeled cell. We demonstrated a membrane location for the ER with these techniques ( Figure 5 ). Note again the punctate appearance of the cell in Figure 5A and the asymmetric mER distribution, especially pronounced in the cell in Figure 5B Figure 5A ) gives the appearance of signal being present deeper in the cell. However, our labeling techniques preserve the integrity of the plasma membrane and do not allow endocytosis during the course of the experiment, thus assuring us that the labeling seen is on the cell surface.
cells (especially in
E2-BSA is a preparation in which the ligand is covalently coupled to BSA; thus it cannot enter the cell and should bind only to cell surface receptors. This conjugate was then additionally coupled to fluorescein (FITC) for fluorescence microscope studies. When cells are labeled with this reagent, the appearance is again punctate, uneven, and heterogeneous as was shown for labeling with Cy3-ER Ab (Figure 4 ). When these cells are double labeled with both reagents, exactly the same cells are labeled with an identical pattern of staining ( Figure 6 ). That these two very different labeling techniques (one based on epitope recognition, the other on steroid binding) label the same cells is very strong evidence that our immunological identification of mER is not artifactual. (48) . We again used ligands conjugated to a large protein molecule (BSA) to prevent access of our small lipophillic ligand to the intracellular space while exposing it to the cell surface. Impeded ligands therefore represent a way (in addition to the demonstration of the rapidity of the response) to suggest that signaling occurs at a membrane receptor. We applied E2-BSA to our cell system and assayed PRL release. Immobilized ligand caused rapid PRL release from GH3/B6 cells (Figure 1) . By 1 min, PRL release in the presence of 5 ng/ml E2-BSA exceeds that of BSA controls ( Figure 4A ), though this is not statistically significant (p= 0.07). Increased PRL release is significant at 5 min. Figure 4B shows that the effect of E2-BSA is also dose dependent but is multiphasic, with maximal stimulation of PRL release at 1 ng/ml. The multiphasic aspect of the effect reveals that there may be a number of mechanisms activated by this ligand and that the effective doses for such alternative mechanisms may be different. Lieberherr et al. (18) have shown biphasic effects of E2-BSA on mobilization of intracellular calcium in rat osteoblasts. Although it is difficult to estimate the concentration of estrogen available to the cells in this reagent (due to steric considerations), the maximum available estrogen in 1 ng/ml E2-BSA is 0.3 nM (given the maximum 20:1 ratio of estrogen to BSA in this preparation). Thus, this reagent is more potent in eliciting PRL release than is unconjugated 17[-E2. We are not the first group to see this tetheredsteroid phenomenon. Dluzen and Ramirez (59) showed that progesterone immobilized on BSA was more potent than free progesterone in releasing dopamine from striatal slices. Why the conjugated steroid is more effective can only be a matter of speculation at this time since surface receptors represent a new class of steroid-binding molecules. Estrogen moieties packed onto a carrier molecule present a higher local concentration of estrogen to surface receptors, and a single BSA bearing many steroid molecules could activate several clustered surface receptors; clustering of receptors is important for action in some signal transduction systems (58) . The covalent attachment of steroid to a large protein could also prevent the signal from being processed away and thus circumvent subsequent down-regulation of the response. Finally, the 6-substituted E2 may be a more potent steroid at such a membrane binding site. Alternative ligand specificities for membrane steroid receptors have been demonstrated (39, 45, (60) (61) (62) .
Trypsin digestion removes membrane ER labeling ( Figure 4C ) and therefore would be expected to affect a function mediated by this receptor. Figure 2 shows that trypsin treatment also vitiates the estrogen-induced PRL release; this result suggests that the portion of the mER corresponding to our antigenic peptide is on the outside of the cell. Also, because trypsin has no access to the intracellular receptors, its action on this antigen supports membrane localization. This action of trypsin also required us to seek other means of releasing substrate-attached cells for immunoselection techniques.
Immunosdection by and Regulaton ofmER Expression
Since mER is only expressed on a relatively small percentage of the cell population, we sought a mechanism for purifying and propagating mER-bearing cells. Figure 7 shows the appearance of cells enriched or depleted for mER after a representative immunopanning experiment. In the experiment depicted in Figure 6 , 98% of selected cells (all cells in the shown field) were enriched for carrying mER ( Figure  6A ); mER cells were sparsely and weakly labeled ( Figure 6B ). In addition, the staining intensity of mER+ cells is very strong. Figure 8A shows that the average numbers of cells immunoselected with either anti-ER Ab are about 80% positive for mER compared to about 20% very weakly positive cells in depleted fractions (refer to Figure 7 for staining intensity). This result assures us that the immunopanning protocols, which were previously designed and used for mGR-containing cells (43, (45) (46) (47) 63) , are generally applicable to other plasma membrane-resident steroid receptors in other cell types. Figure 8B shows that when cells are immunopanned (pooled results from both Abs) and immediately placed in either DM1 transcription of endogenous PRL mRNA is near a maximal rate at this time (66) although it is not known how soon this is available for translation. Maurer (67) 
